BioSpace News Archive

Centene Corporation (NYSE: CNC) today will host its investor day to outline its 2023 financial guidance as well as provide updates on its long-term strategic plan, designed to deliver long-term shareholder value.

Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds.

Akumin Inc. is pleased to announce that John Wagner and Lawrence Ross Sinclair will join its board of directors effective January 1, 2023.

BioStem Technologies Inc. is pleased to announce that its common shares have been successfully up-listed from the OTC Pink Sheet Open Market to the OTCQB Venture Market (the “ OTCQB ”) by the OTC Markets Group Inc.

Moderna, Inc.(Nasdaq:MRNA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the marketing authorization (MA) to include a booster dose of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), at the dose level for children (6-11 years) of 12.5mcg/12.5mcg (0.25 mL) at least three months after the last prior dose of a COVID-19 vaccine.

Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) today announced its 2023 Humira® formulary recommendations.

On Jan. 26, 2023, the U.S. Food and Drug Administration will hold a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to consider whether and how the composition for primary doses of the currently available COVID-19 vaccines should be modified and how and whether the composition and schedule for booster doses should be adjusted moving forward.

The global biotechnology market size was exhibited at USD 859.94 billion in 2022 and it is expected to hold around USD 1,683.52 billion by 2030, growing at a CAGR of 8.7% from 2022 to 2030.

Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2023 at approximately 8:00 A.M. Eastern time on Monday, February 6, 2023.

The U.S. Food and Drug Administration approved Adstiladrin, a non-replicating adenoviral vector‑based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin -unresponsive non-muscle-invasive bladder cancer with carcinoma in situ with or without papillary tumors.